Women who knew PCOS as a lifelong health burden now have a new name for it. A global team led by Monash University endocrinologist Prof. Helena Teede has changed polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome, or PMOS. The new name was published in The Lancet on May 12 and explained in fresh public health reporting from Canada and Australia.
The change is not a small language edit. It shifts the condition away from the old focus on ovarian cysts and toward the wider endocrine and metabolic problems many patients face.
PMOS is linked with diabetes, heart disease, depression, infertility, pregnancy complications and lower quality of life. It affects about one in eight women worldwide, and about one in 10 Canadian women. The World Health Organization estimates that 70 percent of affected women have never received a diagnosis.
Doctors and patient advocates have argued for years that the old name was misleading. PCOS suggested the condition was mainly about cysts on the ovaries. The source article explains that the issue is not an increase in abnormal ovarian cysts, but follicles around partly developed eggs after hormonal or chemical messenger disruption.
That misunderstanding mattered. It shaped how patients were seen, how doctors explained symptoms, and how the condition was funded and studied. A narrow ovarian label left many women with weight changes, acne, excess hair growth, anxiety, depression and metabolic risk feeling badly heard.
The new name points to a wider body system problem. PMOS reflects disturbances involving insulin, androgens, neuroendocrine signals and ovarian hormones. It also recognizes that the condition can affect skin, mental health, fertility, pregnancy and long-term metabolic health.
The name change followed a large global process. According to the source article, more than 22,000 health professionals and people living with PMOS took part in surveys and workshops. The work also involved 56 academic, clinical and patient organizations.
A 2025 survey helped move the process forward. It found that 85.6 percent of patients and 76.1 percent of health professionals supported the change.
The transition will not happen overnight. A three-year changeover is planned, with care expected to expand across endocrinology, gynecology, dermatology, pediatrics and primary practice. The AskPMOS app is also part of the wider information effort for women seeking expert guidance.
The larger test now sits with clinics, researchers and health systems. A better name can help, but only if it leads to earlier diagnosis, better listening and care that sees the whole patient.
